JMP Securities Cuts Prothena (NASDAQ:PRTA) Price Target to $81.00

Prothena (NASDAQ:PRTA – Get Free Report) had its price objective dropped by research analysts at JMP Securities from $83.00 to $81.00 in a report issued on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective indicates a potential upside of 115.71% from the company’s […]

Related Keywords

United States ,Karinl Walker ,Brandons Smith , ,York Mellon Corp ,Securities Exchange Commission ,Prothena Corporation ,First Light Asset Management ,Cantor Fitzgerald ,Dimensional Fund Advisors ,Hightower Advisors ,Nasdaq ,Get Free Report ,Exchange Commission ,New York Mellon Corp ,Tower Advisors ,Fund Advisors ,Light Asset Management ,Prothena Daily ,Prothena ,Nasdaq Prta ,Pprta ,Medical ,Lower Price Target ,Jmp Securities ,